All In Biotech

BLA 761164 · Recordati Rare Diseases, Inc.

Enjaymo

Sutimlimab-Jome · Injection · Classical Complement Pathway Inhibitor

NovelBreakthrough therapyPriority reviewOrphan

CDER novel approval, Feb 4, 2022: To decrease the need for red blood cell transfusion due to hemolysis in cold agglutinin disease

Last checked: Nov 20, 2026Latest source record: Feb 8, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2022

Feb 4, 2022

Approved uses

2

Original approval plus efficacy supplements

Registered trials

3

3 Phase 3, 0 recruiting

FAERS reports

321

180 serious, 54 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Mar 2, 2026.

ENJAYMO is a classical complement inhibitor indicated for the treatment of hemolysis in adults with cold agglutinin disease (CAD). ( 1 ) Cold Agglutinin Disease ENJAYMO (sutimlimab-jome) is indicated for the treatment of hemolysis in adults with cold agglutinin disease (CAD).

Mechanism: Sutimlimab-jome is an immunoglobulin G (IgG), subclass 4 (IgG4) monoclonal antibody (mAb) that inhibits the classical complement pathway (CP) and specifically binds to complement protein component 1, s subcomponent (C1s), a serine protease which cleaves C4. Sutimlimab-jome does not inhibit the lectin and alternative pathways. Inhibition of the classical complement pathway at the level of C1s prevents deposition of complement opsonins on the surface of RBCs, resulting in inhibition of hemolysis in patients with CAD.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jan 25, 2023 Supplement 3 · Efficacy · priority review Breakthrough therapyOrphanLetterLabel
  • Feb 4, 2022 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyOrphanLabelLetterReview
1 products under this application
  • ENJAYMO · SUTIMLIMAB-JOME 1,100MG/22ML(50MG/ML) · INJECTABLE, INJECTION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Sutimlimab" as an intervention, any sponsor and status, largest first.

All 3 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use39
  • haemoglobin decreased23
  • arthralgia20
  • fatigue18
  • death16
  • haemolysis16
  • condition aggravated15
  • drug ineffective13
  • headache13
  • covid-1912
  • cyanosis11
  • nausea11

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
202234
202359
202473
202572
202683

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Enjaymo (Sutimlimab-Jome)

2024 spending

$1.7M

Beneficiaries

12

75 claims

Per beneficiary

$142,475

$84.85 per unit

View as table
YearSpending
2020$0
2021$0
2022$336,833
2023$1,291,730
2024$1,709,695

Part B: Enjaymo (Sutimlimab-Jome) · HCPCS J1302

2024 spending

$33.9M

Beneficiaries

180

2,560 claims

Per beneficiary

$188,146

2024 ASP limit $17.94 per unit

View as table
YearSpending
2020$0
2021$0
2022$3,199,085
2023$23,534,880
2024$33,866,257

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 10 on PubMed

Sponsor: Recordati Rare Diseases, Inc.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.